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Abstract:
Salen Mn complexes, including EUK-134, EUK-189 and a newer
cyclized analog EUK-207, are synthetic SOD/catalase mimetics that have
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beneficial effects in many models of oxidative stress. As oxidative stress is
implicated in some forms of delayed radiation injury, we are investigating
whether these compounds can mitigate injury to normal tissues caused by
ionizing radiation. This review describes some of this research, focusing on
several tissues of therapeutic interest, namely kidney, lung, skin, and oral
mucosa. These studies have demonstrated suppression of delayed radiation
injury in animals treated with EUK-189 and/or EUK-207. While an antioxidant
mechanism of action is postulated, it is likely that the mechanisms of
radiation mitigation by these compounds in vivo are complex and may differ
in the various target tissues. Indicators of oxidative stress are increased in
lung and skin radiation injury models, and suppressed by salen Mn
complexes. The role of oxidative stress in the renal injury model is unclear,
though EUK-207 does mitigate. In certain experimental models, salen Mn
complexes have shown “mito-protective” properties, that is, attenuating
mitochondrial injury. Consistent with this, EUK-134 suppresses effects of
ionizing radiation on mitochondrial function in rat astrocyte cultures. In
summary, salen Mn complexes could be useful to mitigate delayed radiation
injury to normal tissues following radiation therapy, accidental exposure, or
radiological terrorism. Optimization of their mode of delivery and other key
pharmaceutical properties, and increasing understanding of their
mechanism(s) of action as radiation mitigators, are key issues for future
study.
Keywords: salen manganese complex, radiation injury, radiation mitigation,
catalytic antioxidant.

II. Rationale for testing Salen Mn complexes as
radiation mitigators
Radiation therapy, besides destroying the tumor cells that are
its intended target, can also cause delayed injuries, some very serious
or even lethal, to normal tissues. There is a need for therapeutic
agents to prevent such normal tissue injury. Preferably, these agents
would be administered well after irradiation, so as not to risk
interfering with the anti-tumor effects of the radiation therapy [1].
While the mechanisms of delayed radiation injury are not well
understood, evidence suggests that oxidative stress is involved [2–4].
Therefore, we and others have studied synthetic agents that neutralize
the reactive oxygen species (ROS) superoxide and hydrogen peroxide
as potential therapeutic agents to mitigate normal tissue injury
resulting from ionizing radiation. This review focuses primarily on
radiation mitigation studies employing one class of synthetic ROS
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scavenger, a class of synthetic metal-containing compounds known as
salen Mn complexes [5].
It has long been known that exposure of biological materials to
ionizing radiation produces a burst of reactive oxygen species (ROS),
including superoxide, hydrogen peroxide, hydroxyl radical, and singlet
oxygen. These highly reactive species oxidize cellular macromolecules,
such as DNA, producing lethal damage [6]. However, what has been
less appreciated until recently is the potential role of chronically
generated ROS in delayed radiation-induced damage [2–4]. Such
injury, including fibrosis, necrosis, atrophy, and vascular damage,
occurs months to years after exposure to radiation. Clinically relevant
target tissues for radiation injury include the skin, kidney, lung, oral
mucosa and brain. There is evidence for cumulative ROS and reactive
nitrogen species (RNS)-mediated damage, for example lipid
peroxidation and protein tyrosine nitration, in such target tissues
following irradiation. There is also evidence for proinflammatory
processes, namely acute activation of stress-sensitive signaling
transcriptional events and cytokine production [4, 7]. Indeed,
infiltrating inflammatory cells would serve as one likely source of
damaging ROS. Another potential source of ROS is the mitochondria,
especially when dysfunctional. Evidence indicates not only that
radiation leads to mitochondrial injury, but also that delivery of
antioxidant enzymes to the mitochondria through gene therapy
techniques can protect against delayed radiation damage in vivo [2],
and a mitochondrially targeted antioxidant reduces radiation injury in
cell culture [8]. Therefore, both proinflammatory processes and
mitochondrial dysfunction are implicated in delayed radiation injury.
These findings suggest that agents that interrupt these damaging
subcellular processes might have considerable therapeutic benefit
against the damaging effects of radiation exposure.
Such considerations have led to our investigation of salen Mn
complexes as potential mitigators of delayed radiation injury. As
discussed further below, prior data showed that treatment with these
compounds suppressed proinflammatory processes, inhibited
mitochondrial damage, and reduced oxidative changes in various
experimental models not involving radiation injury.
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Currently the only FDA-approved drug for preventing radiation
injury is amifostine (Ethylol®), which is usually administered
intravenously or subcutaneously and, according to current clinical
guidelines, prior to radiation exposure [9]. It acts as a free radical
scavenger, but may have additional mechanisms of action such as
modulation of antioxidant enzymes [9, 10]. No agent has yet been
FDA-approved to prevent radiation injury when administered after
radiation, a property referred to as “radiation mitigation”. In the
radiation countermeasures area, mitigators refer to therapies begun
after irradiation but prior to clinical evidence of injury. This is to
distinguish them from protectors, which are given prior to irradiation,
and from treatment agents, which are used after there is clinical
evidence of injury [11]. Salen Mn complexes, while not yet approved
for human use, are interesting candidates for development with
potential advantages over amifostine. One major advantage is their
ability, as summarized in this review, to mitigate delayed radiation
injury when given days to weeks after irradiation.
Salen Mn complexes are a class of synthetic low molecular
weight agents that mimic the antioxidant enzymes superoxide
dismutase (SOD) and catalase, scavenging superoxide and hydrogen
peroxide, respectively [5]. Data, including structure-activity
relationship findings in vitro and in vivo, indicate that the hydrogen
peroxide scavenging property, namely catalase activity, is a more
important parameter than SOD activity in determining certain
cytoprotective effects of salen Mn complexes, though other factors
such as pharmacokinetics and cytotoxicity are also important [5]. In
addition, it’s been shown that salen Mn complexes can scavenge
reactive nitrogen species (RNS) through mechanisms analogous to
their catalase activity [12], a property of potential relevance to their
ability to attenuate protein nitration in oxidative injury models [13,
14]. Overall, this combination of properties (low molecular weight,
catalytic scavenging mechanism, and activity against multiple
damaging species) provides advantages for salen Mn complexes over
other antioxidants, such as noncatalytic ROS scavengers or
proteinacious antioxidant enzymes [15, 16]. Prototype salen Mn
complexes EUK-8 and the improved catalase mimetics EUK-134 and
EUK-189 (Fig 1), are effective in a wide range of models for diseases
involving oxidative stress [6, 17]. In many of these models, salen Mn
complexes were not only functionally protective, but also suppressed
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biochemical indicators of oxidative stress, such as oxidative
modifications of protein, lipids and nucleic acids [13, 18, 19]. EUK-207
(Fig 1) is a “second generation” cyclized salen Mn complex that has
catalytic properties equivalent to EUK-134 and EUK-189, but was
designed for greater stability [17, 18, 20]. Consistent with this, we
have found that EUK-207 attains much higher plasma levels than EUK189 (e.g., when given subcutaneously to rats (Fig 2)). Both EUK-189
and EUK-207 are highly effective at improving a behavioral indicator of
cognitive function and suppressing markers for brain oxidative stress
(e.g. nucleic acid oxidation) in a mouse model for age-associated mild
cognitive impairment [18, 21]. While structure-activity relationship
data and other relevant properties have been published for these
compounds, Table 1 is included to facilitate their comparison. The
Table summarizes key properties of EUK-189 and EUK-207, as well as
Mn porphyrin compounds that are discussed in section IV.
Endogenous antioxidant defense enzymes [6] include three
types of superoxide dismutases (SOD). The cytosolic and extracellular
forms of superoxide dismutase (sod1 and sod3, respectively) are Cu
and Zn containing enzymes. The mitochondrial form (sod2, or MnSOD)
instead has Mn in its active site. Mitochondria-targeted expression of
either sod2 or sod1 protects against radiation injury in a mouse
esophagitis model [2, 22] and mice deficient in sod2 (sod2−/+ mice)
are more vulnerable to radiation lung injury [23]. A mutation leading
to increased production of mitochondria-derived ROS has recently
been shown to make mammalian cells (hamster fibroblasts)
substantially more sensitive to ionizing radiation, and it’s been
hypothesized that radiation-induced disruptions in mitochondrial
oxygen metabolism contributes to radiation injury [24]. Such findings
suggest that a synthetic antioxidant reaching the mitochondria should
have therapeutic benefits in radiation injury. Although salen Mn
complexes were not designed specifically to target the mitochondria,
several studies have shown that the compounds are, indeed, “mitoprotective”. They prolong survival up to 3-fold, protect mitochondrial
enzymes, and prevent oxidative pathologies in sod2−/− mice, an in
vivo model for severe mitochondrial oxidative stress [25, 26]. EUK-189
and EUK-207 were much more effective than other agents tested in
sod2−/− mice, namely, the Mn porphyrin MnTBAP, the reported SOD
mimetic M40403, and the mitochondrial metabolites, with reported
mitoprotective properties, alpha lipoic acid and L-acetyl-carnitine [17].
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Since salen Mn complexes, unlike targeted agents such as MitoQ [27]
and others [8] are not designed to exclusively reach the mitochondria,
they might have broader therapeutic potential because, presumably,
they can also address non-mitochondrial injury mechanisms, such as
proinflammatory processes.
Irradiation of late-responding tissues leads to acute activation of
stress-responsive transcriptional events, leading to production of
inflammatory cytokines mediating an aberrant chronic inflammatory
cascade that ultimately leads to fibrosis or necrosis [4, 7] Production
of such mediators is controlled by “stress-induced” transcriptional
factors including those, e.g. NF-kB and AP-1, which are believed to be
activated by increased ROS. Such events are reminiscent of
proinflammatory processes that mediate tissue injury in many other
pathological conditions, such as infection, ischemia/excitotoxicity, and
environmental stress. Salen Mn complexes are markedly protective
against such forms of tissue injury in vivo, while concomitantly
suppressing activation of “stress-induced” transcription factors in
target tissues [13, 28, 29]. For example, EUK-134 inhibited the
excitotoxic activation of AP-1 and NF-κB secondary to kainic acidinduced seizures, while preventing hippocampal neuronal death [13].
EUK-189 inhibited AP-1 activation in aged rats subjected to mild heatstress, while concomitantly preventing severe liver injury that occurs
in aged, but not young, rats in this experimental system [30]. Salen
Mn complex treatment increased the mean survival time of allogeneic
C57Bl/6 skin grafted into BALB/c mice, reduced pro-inflammatory type
1 alloresponse (IFN-γ) while promoting anti inflammatory type 2
alloimmunity (IL-4 and IL-5) [31]. Tissue transglutamininase 2 is
activated in a pro-oxidative environment, inducing degradation of
PPAR-γ, NF-κB activation and inflammation [32] and treatment with
EUK-134 restored PPAR-γ, levels [33]. Therefore, the suppressive
effects of salen Mn complexes against proinflammatory, injuryassociated transcriptional processes provided another rationale, in
addition to their “mito-protective” properties, for investigating their
benefits in radiation injury models.
Taken together, such findings led to the hypothesis that salen
Mn complexes would mitigate radiation injury to normal tissues.
Proposed mechanisms might involve preventing mitochondrial injury,
suppressing “proinflammatory” processes, inhibiting other forms of
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the
express permission from Bentham Science Publishers.

7

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

oxidative injury to cellular constituents or most likely, complex
combinations thereof.

III. Mitigation of radiation injury by salen Mn
complexes
Cell culture systems
Mitochondrial dysfunction in astrocytes as a model for central
nervous system (CNS) radiation injury - Radiotherapy continues to
be a primary treatment for malignant brain tumors as well as other
neoplasms located in or near the CNS. Consequently, radiationinduced injury to normal CNS tissue is of significant concern and is the
major dose-limiting factor in the treatment of gliomas and other head
and neck tumors. The CNS damage resulting from irradiation is most
often characterized by vascular abnormalities, demyelination and,
ultimately, necrosis, which can be expressed years after radiotherapy
[34]. Although this form of radiation-induced normal tissue injury has
been well described in terms of histological and functional criteria [35,
36], its pathogenesis remains poorly understood. Delayed cell death
and tissue injury can result from a number of reactive processes, but
accumulating data suggest that an initiating source of these delayed
effects can be mitochondrial dysfunction. Mitochondrial damage has
been implicated in a number of neurological conditions, namely
trauma, ischemia, excitotoxic insults and neurodegeneration, and CNS
lesions following radiation share some similarity to these other forms
of injury [37]. The ultimate consequences of mitochondrial injury
include insufficient ATP production and increased ROS generation. With
its high energy demands and rate of oxidative metabolism, the CNS is
particularly susceptible to these impairments. Rat astrocyte cultures
were used to investigate the role of mitochondrial dysfunction in CNS
radiation injury. Astrocytes are the most prevalent phenotype in the
CNS, outnumbering neurons by approximately 9:1. They have
numerous functions in the normal CNS [38] including a critical role in
the protection of endothelial cells, oligodendrocytes and neurons from
oxidative or excitotoxic injury [39–41]. Given their key functions, it
would be expected that the response of astrocytes to radiation would
have a major impact on the radiation response of the CNS as a whole.
The astrocytes, which are normally relatively non-proliferative in vivo,
were tested for radiation injury as confluent cultures, thus eliminating
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the complicating variables of cell cycle delay and redistribution. These
cells, irradiated at 5, 10, or 30 Gy, showed no significant loss of
viability, consistent with their non-proliferative state (data not shown).
However, the astrocyte cultures developed mitochondrial
abnormalities, particularly at the higher radiation doses. These
abnormalities included decreased ATP levels and increased
mitochondrial mass per cell (Fig 3), both known consequences of
mitochondrial impairment. The irradiated astrocytes also developed
changes in respiratory chain activities, namely decreases in complex II
and III and, atypical of other forms of mitochondrial toxicity, an
increase in complex I (Fig 4). Generally, these changes began to
appear 1 day post-irradiation, persisting for at least 7 days (data not
shown). When given to the cells immediately after 30 Gy irradiation,
the salen Mn complex EUK-134 attenuated, in a dose-dependent
manner, radiation-induced effects on respiratory complex activities
(Fig 4). This “mito-protection” was significant even when EUK-134 (50
μM) was added to cultures up to 12 hr after irradiation (30 Gy) (Fig 5).
These data provide direct evidence for radiation-induced nonlethal
mitochondrial abnormalities in astrocytes, potentially sufficient to
cause sustained ROS production and other injurious effects.
Furthermore, these data support the use of “mito-protective” salen Mn
complexes to mitigate such injury. Whether these findings extend to
key target cells for delayed radiation injury in other tissues remains to
be investigated. However, Vorotnikova et al. [42] showed that several
compounds with SOD and catalase activities, including the salen Mn
complexes EUK-189 and EUK-207, inhibited radiation-induced
apoptosis in bovine adrenal capillary endothelial cell cultures. While
the mechanism of such anti-apoptosis is not well understood, previous
findings have shown that staurosporine induced apoptosis, also
inhibited by salen Mn complexes, is mediated by oxidative stress [43].
More recently, EUK-207 was found to prevent several radiationinduced injuries in human microvascular endothelial cell cultures [44].
These findings may be relevant to the potentially broad applicability of
these agents as radiation mitigators, since the vascular endothelial cell
is regarded as being an important target for radiation injury in several
normal tissues [45].
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Animal Models
Pulmonary radiation injury - The lung is one of the most susceptible
organs to potentially debilitating radiation injury. The functional effects
of pulmonary radiation injury are normally separated into two phases.
Radiation pneumonitis generally occurs within 2 to 4 months and
fibrosis tends to develop 4 to 6 months after irradiation [46]. Acute
pneumonitis is treated with steroids, but can be life-threatening even
with treatment. Lung fibrosis is permanent and progressive and can
ultimately lead to respiratory distress, pulmonary hypertension, right
heart failure and even death. Though the mechanisms are not well
understood, extensive data suggest that pneumonitis and fibrosis may
result from a cycle of chronic inflammation and oxidative damage
initiated by radiation exposure to the lung [4, 7, 47, 48].
In Sprague-Dawley rats subjected to partial lung irradiation,
EUK-189 given by a single subcutaneous (sc) injection suppressed
micronucleus formation, an indicator of DNA damage in lung
fibroblasts, measured 18 hr later [49]. This suppression of micronuclei
counts did not persist without subsequent EUK-189 injections, but it
was observed even if the EUK-189 injection was delayed until two
weeks after irradiation. These findings were consistent with
micronucleus formation resulting from an ongoing cycle of injury and
repair, consistent with (as discussed above) a continuous “cascade” of
ROS formation after irradiation. This theory also implies that sustained
treatment with an ROS scavenger such as a salen Mn complex, would
be required in order to have a significant impact on lung injury. Thus,
despite an intriguing report that a single injection of EUK-189
enhanced hematopoietic survival in lethally irradiated mice [50], the
single injections of EUK-189, regardless of timing, did not have a
substantial effect on the clinical outcome of radiation lung injury in the
rats [49]. Similarly, in a mouse CNS radiation injury model, a single
injection of EUK-134 failed to show radioprotective efficacy in
preventing loss of proliferating neuronal precursors [51].
Consequently, most subsequent studies with salen Mn complexes have
increased drug exposure through longer periods of therapy, either by
daily sc injection or by continuous sc infusion utilizing Alzet osmotic
pumps.
One such study [52], also in Sprague-Dawley rats, utilized the
newer generation compound EUK-207, given by continuous sc infusion.
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Rats received 10 Gy thoracic irradiation and were monitored for
indicators of lung injury for 28 weeks, with animals sacrificed for tissue
collection at various time points (0, 4, 8 and 28 weeks). They received
EUK-207 (~8 mg/kg-day continuous sc infusion) for 14 wks, beginning
1 hr after irradiation. As shown in Fig 6, compared to the unirradiated
controls, irradiated rats showed an increase in breathing rate,
essentially consisting of two rises, and persisting throughout the
analysis period. EUK-207-treated irradiated rats, in contrast, showed
normalized breathing rates. It was of interest that the normalization of
breathing rate persisted until at least 28 wks, even though drug
treatment stopped at 14 wks. A well-established biochemical indicator
of DNA damage due to oxidative stress, the oxidized nucleic acid 8OHdG, was significantly higher in lungs from irradiated, versus
unirradiated, rats at all time points (Fig 7). EUK-207 treated irradiated
rats showed substantially lower 8-OHdG levels, relative to irradiated
control rats, indicating suppression of DNA damage due to oxidative
injury. It was also noted that even unirradiated controls showed a
slight increase in 8-OHdG over time, perhaps due to some age-related
changes. As an indicator of lung fibrosis, collagen levels were
monitored in lung tissue using Masson Trichrome stain imaging (not
shown) and hydroxyproline content (Fig 8). As the figure shows, lungs
from untreated irradiated rats had greatly increased hydroxyproline
levels at 28 wks, and the levels were significantly reduced by EUK-207
treatment. Similar results were obtained with Masson Trichrome
staining [52]. Interestingly, and of possible relevance to an antifibrotic effect, the lungs from EUK-207 treated irradiated rats also had
significantly lower TGF-beta levels, comparable to those of
unirradiated rats, at 28 wks [52]. The ED-1 stain for activated
macrophages was also significantly decreased by treatment of EUK207 compared to the elevated level of ED-1 stain in irradiated rats
only. The effects of drug treatment on other cytokines (IL-1 alpha and
beta, IL-6, and TNF-alpha) were less marked, though there were some
decreases [52]. Along with EUK-207, Mahmood and colleagues also
tested the effects of a diet of genistein, a soy isoflavone with
antioxidant and anti-inflammatory properties, and combined genistein
with EUK-207 in a third treatment group. Although there were slight
differences among them, all treatment groups showed similar effects
on lung injury and oxidative stress parameters [52]. Thus, two
chemically quite different agents, hypothesized to have similar
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mechanisms of action, showed significant mitigating effects against
radiation injury to the lung.
In another type of rat model for radiation pneumonitis,
WAG/RijCmcr rats were exposed to 11Gy total body irradiation (TBI)
followed by syngeneic bone marrow transplant (BMT). This protocol
avoids death caused by hematopoietic injury. Under such conditions,
the animals develop pneumonitis by 6 weeks post-irradiation and
those surviving the lung injury go on to develop radiation-induced
renal injury, as discussed further in the following section. When this
strain of rats is exposed to whole thoracic radiation, the resulting
pulmonary injury is indicated by increased breathing rate, right
ventricular hypertrophy, increased pulmonary vascular resistance and
other vascular abnormalities [53, 54]. This radiation-induced
pneumonitis is mitigated by the angiotensin converting enzyme (ACE)
inhibitor captopril [55]. Using the TBI/BMT protocol, a combination
therapy of a suboptimal dose of captopril (100 mg/m2/day) and EUK207 (1.8 mg/m2/day), starting 7–10 days post irradiation and
continuing for 8 weeks, showed promise in mitigating radiationinduced pneumonitis [56]. The radiation- induced increase in right
ventricular hypertrophy and pulmonary vascular resistance were
decreased by EUK-207 and captopril, either alone or in combination
[57]. In addition, while isolated perfused lungs from irradiated rats
exhibit lower ACE activity than sham (unirradiated) controls, this
radiation-induced drop in ACE activity was prevented by EUK-207 (Fig
9). As shown previously using whole thoracic irradiation protocols, ACE
activity measured in perfused lungs is lower after irradiation,
suggesting a decrease in the number of endothelial cells or an
endothelial cell dysfunction [53, 58]. The finding that EUK-207 therapy
prevents the loss of ACE activity is consistent with a preservation of
functional vasculature in the irradiated rats, perhaps via prevention of
endothelial cell loss. Consistent with this hypothesis, Ghosh et al. [53]
demonstrated, using imaging techniques, substantial loss of vessel
density in irradiated lungs. Other options such as a direct induction of
ACE expression by EUK-207 are, in addition, possible.
Similar to the findings in rats, EUK-207 has mitigating effects in
mouse models for radiation lung injury. Williams et al [59] have
developed mouse models in which C57BL/6J or CH3/HeJ mice receive
5Gy to total body followed by 10Gy to lung only. This method causes
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lethal lung injury while minimizing death due to hematopoietic injury.
The response of these two strains to radiation is being studied by
monitoring indicators of pulmonary injury and plasma cytokine levels
for up to 15 months. When administered by daily sc injection using an
acute (days 1 to 7 post-irradiation) or chronic (from wk 8 to 26)
administration, EUK-207 (30 mg/kg-day) improved survival in both
strains of mouse, especially when co-administered with simvastatin.
Survival was associated with a decrease in inflammatory infiltration
and down-regulation of the proinflammatory cytokines IL-1-beta and
MCP-1 [59].

Renal radiation injury - Months to several years after undergoing
bone marrow transplant requiring TBI, some patients develop renal
failure and there is considerable evidence that irradiation plays a
causal role [60]. As discussed above, a TBI/BMT protocol induces
radiation nephropathy in WAG/RijCmcr rats that is delayed in onset by
weeks to months. Loss of renal function in this model is indicated by
the primary clinical endpoints including azotemia (measured as
increased Blood Urea Nitrogen, BUN), proteinuria (and the urine
protein to creatinine ratio, UP/UC), and hypertension. Moulder and
colleagues have reported that captopril and other modulators of the
renin-angiotensin system mitigate renal injury [61, 62], while a variety
of other agents, including several antioxidants [63] are ineffective.
Despite the lack of effect of other antioxidant approaches, including a
genistein diet [63], several experiments were conducted to evaluate
salen Mn complexes as potential mitigators in the rat renal injury
model [64].
In the first series of experiments, the compounds were
administered by continuous sc infusion; therapy was for 12 wks,
beginning 3 wks after irradiation, with Alzet osmotic pumps delivering
a constant volume, resulting in a dose of 8 to 10 mg/kg-day. The first
experiment tested only EUK-189, and it was found to have no
significant mitigating effect, consistent with what was seen with other
antioxidant approaches in the radiation nephropathy model [63]. A
second experiment compared EUK-189 and EUK-207. As shown in Fig
10, EUK-207 mitigated renal injury caused by 9 Gy TBI, while, again,
EUK-189 had no significant effect. It is interesting to note that this
mitigation was observed 26 wk after irradiation, 11 wks after drug
treatment had ended. In a third experiment, employing 10 Gy TBI to
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accelerate renal injury, EUK-207 was compared to captopril, the latter
given orally in the drinking water (12 to 15 mg/kg-day), in the same
schedule as that used for EUK-207. As shown in Fig 11, mitigation by
EUK-207 was comparable to that of captopril when measured at 13
wks, though with a lesser degree of effectiveness at 17 wks, 2 wks
after termination of drug therapy.
As discussed above, captopril and other agents acting on the
renin-angiotensin system are regarded as the “gold standards” for
mitigating radiation-induced renal injury, whereas a variety of other
antioxidant agents have shown no benefit. Thus, the activity of EUK207 in the kidney is of particular interest, as is the lack of effect of
EUK-189. This finding differs from those in a mouse age-associated
cognitive impairment model, in which EUK-189 and EUK-207 showed
comparable efficacy, including dose-dependency [21]. Perhaps in the
renal model the greater plasma half-life of EUK-207, versus that of
EUK-189 (Fig. 2), is important for mitigating renal injury, supporting a
vascular site of action for the compounds in the radiation nephropathy
model. It was noted during the sc infusion studies that the dose of
EUK-207 employed in the pumps caused a skin reaction in a subset of
irradiated rats, in some cases requiring pump removal. Lower doses
(about 2 mg/kg-day) were found to be ineffective in mitigating
radiation nephropathy. This is contrast to the lung and skin models in
the same strain of rats, where this lower dose range of EUK-207 did
cause substantial mitigation of radiation injury.
To test an alternative method of delivery to the infusion pumps,
an experiment was conducted using sc daily injections of EUK-207,
beginning 48 hr after irradiation and continuing for 10 wks. As shown
in Table 2, EUK-207 at 30 mg/kg per day showed significant mitigating
activity, whereas lower doses did not. The effective dose of EUK-207,
although well tolerated in other rodent models, also caused localized
skin reaction hindering its repeated injection at the same site.
Apparently, the compromised skin in TBI-treated WAG/RijCmcr rats is
vulnerable to this reaction, the mechanism of which is not yet
understood. In another study similar to that described in Table 2, EUK207 was combined with captopril at sub-optimal doses (10 mg/kg-day
sc and 150 mg/l in drinking water, respectively). The combination
showed no more activity than the captopril alone, suggesting a lack of
additivity or synergy between the two treatments. Such data suggest
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that the lower dose of EUK-207 given by daily injection, 10 mg/kgday, is ineffective. Nonetheless, the higher dose (30 mg/kg-day sc
injected or 8–10 mg/kg-day by continuous sc infusion) does have
substantial mitigating activity in the renal injury model.
However, efficacy of salen Mn complexes would not necessarily
have been predicted because the mechanism of renal injury in this
model, particularly the involvement of oxidative stress, is in question.
A study examining several indicators of oxidative injury, including 8OHdG and protein carbonyl, failed to find evidence for increased
oxidative stress in irradiated, versus unirradiated rats in this TBI/BMT
model [65]. As the authors concluded, “if chronic oxidative stress is
part of the pathogenesis of radiation nephropathy, it does not leave
widespread or easily detectable evidence behind”. Results in the
radiation nephropathy model contrast with those in the radiationinduced pulmonary injury model [52], where there was a clear
increase in 8OHdG levels in lungs from irradiated rats, and a
substantial decrease with EUK-207 treatment. In addition, as noted
above, EUK-207 and genistein had comparable effects in the lung
injury model [52], whereas genistein and several other antioxidants
were ineffective in the renal model [63]. Such observations, while not
excluding its involvement, bring into question the importance of
oxidative stress, and its mitigation, in the renal injury model. The
mitigating effects of EUK-207 might involve another mechanism
altogether but, in any event, EUK-207 was not as effective as captopril
in this model. Further supporting its use as a mitigator of radiation
renal injury, captopril is an FDA-approved drug that has been used
widely as an antihypertensive, and its safety has been established in
patients undergoing TBI in preparation for bone marrow
transplantation [66]. While EUK-207 may also be of therapeutic use to
mitigate renal radiation injury, its use as an adjunct or alternative
therapy to captopril is not, to date, well-supported by the rodent
model data.

Oral mucosa - Oral mucositis is a dose-limiting toxicity in patients
receiving chemotherapy or localized radiation treatment for head and
neck cancers [67, 68]. ROS have been an interventional target for the
prevention and treatment of mucositis, with N-acetylcysteine as one
agent under study. The ability of EUK-189 to mitigate radiationinduced mucositis was tested in a hamster model, performed as
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described previously [69]. EUK-189, as compared to EUK-207, is
particularly attractive as a topically administered agent because of its
greater lipophilicity (Table 1) as well as its shorter plasma half-life
(Fig. 2). The latter property should help to minimize any unwanted
systemic effects in an agent intended to act locally. Briefly, the cheek
pouches of anesthetized hamsters were everted to expose the oral
mucosa and the surface was irradiated with a single exposure of 35
Gy. This resulted in severe to moderate oral mucositis by 15 days.
EUK-189 was administered by two methods in this study. One was a
daily sc injection (30 mg/kg), given immediately after irradiation and
each day thereafter, through day 14 (with day 0 being the day of
irradiation). A second method utilized topical administration. EUK-189
solutions in water, at three different concentrations (3.3, 10 and 30
mg/ml) were applied four times on each day (from day 0 til 14) in the
following manner: one observed application, where 0.2 ml EUK-189
solution was applied directly to the mucosa of an anesthetized
hamster; three blind applications, where 0.3 ml of EUK-189 solution
was delivered into the cheek pouch of the conscious animal. Vehicle
(water) was administered to control groups in an analogous manner.
Exposed buccal pouches were photographed on alternate days,
beginning at day 6 and photographs scored blindly for mucositis
severity, as described [69]. Using this standard 6-point severity score,
a score of greater than 3 in this animal model corresponds to National
Cancer Institute or WHO clinical scores of ≥3 [69], indicating a
clinically significant ulcerative mucositis. Consequently, the data are
presented as the prevalance of a mucositis score of ≥3 [69]. As shown
in Fig 12, both methods of EUK-189 administration resulted in a
significant decrease in mucositis severity. With the topical
administration protocol, the two higher doses of EUK-189 were
effective. This protocol was included because it mimics the way the
drug might be given clinically, with a lozenge or mouth rinse the likely
formulations for patients. The sc administration was included as a
“positive control”, since this route of EUK-189 delivery has shown
efficacy in other pharmacological models. Though some of the “topical”
EUK-189 rinse was probably also swallowed by the animals, it is not
likely that this added to its effect, as EUK-189 is not orally bioavailable
[70].
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It is interesting to note that the prolonged, 15 day,
administration of EUK-189 was effective using both dosing protocols.
In contrast, efficacy in attenuating oral mucositis by the SOD mimetic
M40403, a Mn macrocyclic complex reported to lack catalase activity
[71], was dose-schedule dependent in this model [69]. While M40403,
given by ip injections (30 mg/kg) twice per day, from day -1 to day 3,
mitigated oral mucositis, the mitigation effect was absent when the
compound was given from day -1 to day 15. Also, administration of
M40403 beginning on day 0 was more effective than beginning before
irradiation (day -1), with a day 0 through 3 dosing having the greatest
effect. One can speculate on a number of possible explanations for the
apparent differences in schedule dependence between these two
compounds. One hypothesis is that excess hydrogen peroxide could
prolong mucositis by impairing healing, similar to the complex role
that this ROS is known to play in skin wound healing [72]. Possibly,
extended dosing with the SOD mimetic M40403 resulted in later
increases in hydrogen peroxide, whereas EUK-189 scavenges both
superoxide and hydrogen peroxide. Nonetheless, both mucositis
studies do support the potential value of both classes of ROS
scavenging Mn complexes in mitigating radiation-induced oral
mucositis. Given the commonality in underlying pathogenesis [69], it
is also likely that both compounds would also be efficacious in
attenuating chemotherapy-induced mucositis.

Cutaneous radiation injury - Radiation dermatitis is a consequence
of radiation therapy, for example in breast and lung cancer patients,
and cutaneous radiation exposure can impair wound healing. The
cutaneous injury after radiation exposure involves a combination of
inflammatory processes and alteration of cellular proliferation involving
release of pro-inflammatory cytokines, growth factors, and adhesion
molecules [73]. Furthermore, fibrinogenesis and angiogenesis are
directly inhibited by ionizing radiation. Previous studies indicate that
ionizing radiation causes fibroblasts to show reduced proliferation,
atypical migration, and abnormalities in collagen synthesis [74, 75].
Several studies reported changes in the extracellular matrix
composition after radiation injury affecting the healing time of
wounded skin [76, 77]. Moreover, a growing body of evidence
supports a causative role of oxidative stress in the development of
cutaneous radiation syndrome and delayed healing response following
radiation exposure [3, 7]. Such data imply that salen Mn complexes
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could have beneficial effects in models for cutaneous radiation injury.
Thus, EUK-207 was tested in a rat model for combined radiation
dermatitis and skin wound healing [78–80]. In this model,
WAG/RijCmcr rats were irradiated dorso-ventral with a 15kVp soft xray beam that has a steep dose gradient, a protocol enabling delivery
of high doses (10 to 40 Gy, defined at the upper dermis) to the skin
without significant exposure to internal organs. Rats received full
thickness wounds by punch biopsy within one hour of irradiation.
Dermatitis was scored weekly using a semi-quantitative scoring
system for skin injury [81] and wound closure was monitored by
image analysis of traced wound areas. Irradiated rats developed, in a
radiation dose-dependent manner, cutaneous radiation reactions
ranging in severity from transient erythema (onset 24 hours, duration
1–2 days) to large deep scabs and non-healing ulcers (onset day 21,
duration up to 90 days), plus alopecia (onset day 20, duration up to 90
days) and skin fibrosis (onset day 30, duration entire period of study).
There was markedly impaired wound healing, also dependent on
radiation dose. The peak of acute skin reactions was ~ 30 days. As
reported [78–80]. a number of other assessments demonstrated
radiation-induced changes in extracellular matrix deposition, blood
vessel proliferation, gene expression changes and oxidative stress
indicators in the skin.
EUK-207 was evaluated in this cutaneous combined injury
model, using the 30 Gy radiation dose that, without drug treatment,
induced severe cutaneous injury and wounds that failed to heal over
the 90 day observation period. EUK-207 (~1.8 mg/kg-day) or vehicle
(water) were given by sc Alzet infusion pumps beginning 48 hr after
irradiation and continuing for up to 90 days. As reported [78, 80],
there was a dramatic mitigation effect of EUK-207 on radiation injury,
including improvement of wound healing. Within one month, EUK-207
treated rats had reduced moist desquamation, reduced tissue
inflammation, and increased wound contraction. Unlike the vehicle
treated groups, those treated with EUK-207 showed only slight tissue
fibrosis at 90 days post-irradiation, and interestingly, there was even
growth of new hair within the center of the radiation field. Also unlike
the vehicle treated animals, those in the EUK-207 treatment groups
had wounds that were fully healed.
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While, based on its other in vivo effects, the mitigation of
radiation dermatitis by EUK-207 was not unexpected, the beneficial
effect of an ROS scavenger on wound healing in this combined-injury
scenario would not necessarily have been predicted. ROS, particularly
hydrogen peroxide, have been reported to play key signaling roles to
promote wound healing, and localized transfection of catalase delays
healing in rodents [72, 82]. Yet, in other experiments, excess
hydrogen peroxide impaired healing [72] and transfection with sod2
improved wound healing [83] as did chronic administration of a
mitochondrially targeted antioxidant to aged mice [84]. Thus, the role
of ROS, particularly hydrogen peroxide, and of redox regulation in
cutaneous wound healing is highly complex. Despite this, our study
and others support the notion that selected ROS-scavenging agents
such as EUK-207, given under the right circumstances, can mitigate
radiation-induced skin injury, including facilitating wound healing.

IV. Future directions and challenges
Drug delivery methods
As discussed in this review, salen Mn complexes, especially
EUK-207, mitigate radiation injury to a number of normal tissues. One
important issue to be addressed in their further development as
mitigating agents is the method of drug delivery. Evidence indicates
that systemic use for a number of days, or even weeks, may be
needed for optimal effectiveness. With the chronic, continuous nature
of the oxidative stress that is implicated in delayed radiation injury
[7], this is not at all surprising. It is promising, however, that
mitigating effects of EUK-207 in pulmonary and renal models persist
weeks after drug therapy has ended. Currently, daily injection and
continuous sc infusion are the most effective means of delivery for
salen Mn complexes. Such methods of delivery, even portable infusion
pumps such as those delivering insulin, are tolerated by patients for
certain chronic diseases, but are not the most desirable. Oral
administration, instead, would be very convenient for some of these
indications. Salen Mn complexes, even EUK-207 which has high
stability to gastric solutions (Table 1), are not orally available in
rodents [70]. We [70, 85] and others [86] have described low
molecular weight uncharged Mn porphyrins which have ROS
scavenging properties and also can be orally delivered to rodents. The
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series that we have studied, in particular compounds known as EUK418, EUK-423 and EUK-451, are, like EUK-189 and EUK-207, antiapoptotic in a PC12 cell culture system [70] and mitigate apoptosis of
capillary endothelial cell cultures induced by ionizing radiation [42].
While such studies suggest that these “EUK-400 series” compounds
may be promising for mitigation of radiation injury in vivo they are, as
a class, more cytotoxic than EUK-189 and EUK-207. Their efficacy in
both cell culture systems was limited by their toxicity, with EUK-451
being the most effective Mn porphyrin and the least toxic. But the
salen Mn complexes EUK-189 and EUK-207 were even less toxic,
displaying no cytotoxicity at any of the doses tested. Of course, an
increased toxicity would be tolerable if the compound were
substantially more potent, but these Mn porphyrins were only slightly
more (about 3-fold) potent than salen Mn complexes in the cellular
models [42, 70]. In a preliminary in vivo study, EUK-451,
administered to WAG/RijCmcr rats via drinking water and, as a
positive control, by sc osmotic infusion pumps, did not mitigate
radiation renal injury (Fish, Moulder et al., unpublished data).
However, studies to optimize dosing and pharmacokinetics remain to
be conducted. In addition, the renal injury model, in which, as
discussed above, very few agents show any mitigating activity and the
role of oxidative stress is questionable, is not necessarily the best
choice for testing an unknown agent hypothesized to act as an ROS
scavenger. An orally available Mn porphyrin developed by another
group [87] does show neuroprotective efficacy in a rodent Parkinson’s
disease model [86] suggesting that the approach of investigating low
molecular weight Mn porphyrins still has the potential to lead to
interesting orally bioavailable therapeutic agents. For further
discussion of Mn porphyrins, other chapters in this volume review the
use of this class of Mn-ligand complex to mitigate radiation injury,
including compounds that, like salen Mn complexes, are given by
injection or infusion. For example, a catalytic Mn porphyrin ROS
scavenger known as AEOL 10150 mitigates lung injury caused by
thoracic irradiation in the rat when given by continuous sc infusion
[88, 89].
For some normal tissue radiation mitigation indications, a topical
means of delivering salen Mn complexes, if effective, would be
therapeutically practical. Some data with these compounds are
promising in this regard. In the hamster mucositis model, a topical
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dosing regimen, consisting of direct application of EUK-189 to the
cheek pouch mucosa, showed efficacy equivalent to that of sc
injection. In patients, a lozenge or mouth rinse could be useful to
mitigate oral mucositis. In the cutaneous injury studies described here,
only systemic EUK-207 was tested. However, EUK-189 and EUK-207
can be formulated into a topical preparation that reduces ear
inflammation in the mouse (Doctrow et al., unpublished data).
Furthermore, topical application of an EUK-134 preparation to the skin
of human volunteers was shown to prevent skin lipid peroxidation
caused by UVA exposure [90]. Such data support the future testing of
topical preparations of salen Mn complexes to mitigate cutaneous
radiation injury. Inhaled methods of EUK-207 delivery are also under
investigation, especially for pulmonary radiation injury (Williams,
Finkelstein, Doctrow and colleagues).

Mechanism of action: role of ROS scavenging in
mitigation
As discussed throughout this review, the mechanisms of action
of salen Mn complexes, as with any other mitigator of delayed
radiation injury, are likely to be complex. Increased understanding of
these mechanisms could help in future development of analogs, as well
as improved drug delivery and dosing protocols, optimized for each
specific radiation injury indication. Data in astrocyte cultures support
the hypothesis that the compounds’ “mito-protective” properties are
relevant to delayed radiation injury, though this should be further
studied in other cell types as well as in vivo. Findings in certain models
support the hypothesis that salen Mn complexes are acting as ROS
scavengers in vivo. For example, in one rat lung injury model [52],
EUK-207 treatment mitigated signs of pneumonitis and fibrosis, while
concomitantly decreasing lung levels of oxidized nucleic acid. Similar
mitigation of oxidative-stress associated markers was reported in the
cutaneous injury model [78, 80]. While such associations do not prove
causality they are promising indicators that the ROS scavenging
properties of these agents measured in vitro extend to an ability to
mitigate oxidative stress in vivo. In the renal injury model, however,
the role of oxidative stress is in question [63, 65]; and EUK-207
mitigated renal injury, while numerous antioxidant agents, including
EUK-189, did not. Therefore, for the renal injury model, other
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angiotensin system, should be addressed in future research. More
generally, however, it seems likely that combined therapies using two
or more agents with distinct mechanisms of action are likely to be
more effective than one agent alone for a complex indication such as
delayed radiation injury [59].
The pro-oxidative effects of redox cycling agents, including ROS
scavenging compounds, can potentially cause toxicities or confound
understanding of the mechanism of action in biological systems [6].
Any ability of an ROS scavenger to also generate ROS might be
regarded as a “pro-oxidative” activity. As discussed elsewhere in this
review, the ability of a “pure” SOD mimetic, or the enzyme SOD, to
generate hydrogen peroxide can potentially cause damaging effects. In
an intestinal cell culture model, EUK-8 had a protective effect against
injury caused by acidosis, whereas bovine CuZnSOD alone
exacerbated injury, an effect that was reversed by the addition of
bovine catalase [91]. In general, while pro-oxidative effects of salen
Mn complexes have not been ruled out in all biological contexts, the
toxicity of some analogs in cell culture is not associated with their
inherent catalytic properties but, instead, with other parameters such
as instability and release of toxic metabolites of the ligand [5]. In a
wide range of in vivo models, as reviewed earlier, salen Mn complexes
decrease, rather than increase, biochemical indicators of oxidative
stress such as oxidized nucleic acids and protein tyrosine nitration.
While they suppress signals of ROS “probes” in many instances, under
some conditions salen Mn complexes cause increased fluorescence of
the commonly used “ROS-indicator” dye dichlorofluoroscein (DCF) [51,
92]. This does not appear to be an ROS-generating effect. Instead,
this effect is likely due to the peroxidase activity of salen Mn
complexes, that is, their ability to catalyze oxidation of substrates in
the presence of hydrogen peroxide. Peroxidase enzymes are among
the arsenal of endogenous antioxidant defenses [6] and peroxidase
activity is an inherent component of the hydrogen peroxide scavenging
mechanisms of salen Mn complexes [5], Mn porphryins [93], and
mammalian catalase enzymes [94]. Though it can be oxidized by other
ROS, DCF is considered to be an intracellular “ROS indicator” primarily
because it is an oxidizable substrate whose fluorescence is increased
by endogenous cellular peroxidases acting in the presence of hydrogen
peroxide [6]. In cultured rat neural progenitor cells, Limoli et al [51]
found that EUK-189 caused an increased DCF fluorescence in either
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irradiated or unirradiated cells. This experiment was repeated with two
other salen Mn complexes having comparable SOD activities; EUK-172,
an analog with a high catalase/peroxidase activity, stimulated DCF
fluorescence, while EUK-163, with no significant catalase/peroxidase
activity, did not. If generation of hydrogen peroxide had been the
reason for increased DCF fluorescence, EUK-163, with SOD but no
catalase activity, would have been expected to cause higher, not
lower, fluorescence than EUK-172. This observation supported the
hypothesis that salen Mn complexes can act as functional peroxidases
inside cells acting on oxidizable substrates such as DCF. Essentially,
the compounds are metabolizing, rather than generating, hydrogen
peroxide in the process and, therefore, are not behaving as “prooxidative” agents. Such observations also illustrate the need to
understand the potential artifacts associated with any fluorescent
probe when using it as an indicator substance.

Reaching sites of action: lipophilicity, stability and other
properties
The cellular or subcellular target for a given form of radiation
injury should have considerable influence on the properties required of
a mitigator. As discussed throughout this review, potential cellular and
subcellular sites of action include the vascular endothelial cell and the
mitochondria, respectively. An extravascular site of action, if needed
for a given indication, would require the agent to transit the vascular
wall and permeate tissues. Efforts to improve biological efficacy of
salen Mn complexes have included increasing lipophilicity which should
enhance delivery into cells and across vascular barriers. As a class,
salen Mn complexes are more hydrophilic than lipophilic, though a
modest increase in lipophilicity has been found to increase their
effectiveness in certain experimental models. For example, EUK-189,
while having the same ROS scavenging activities as EUK-134, is more
lipophilic, due to its having ethyoxy rather than methoxy side chains
[5]. This increased lipophilicity is hypothesized to explain why EUK189 is more potent than EUK-134 at preventing neuronal apoptosis
[43] and is more effective as a “mito-protector” in sod2−/− mice [26].
Yet, lipophilicity alone does not determine effectiveness. For example,
EUK-207 which, as discussed above, is more stable than EUK-189 and
is also considerably less lipophilic (Table 1) [17, 70]. Both compounds
showed equivalent potency and efficacy in an age-related cognitive
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impairment model [18, 21], and it was suggested that the decreased
lipophilicity of EUK-207, relative to that of EUK-189, was balanced by
its increased intracellular stability. Indeed, in cell culture studies, EUK207 is more potent than EUK-189 in suppressing apoptosis [70], an
intracellular injury, while having similar potency against extracellularly
generated hydrogen peroxide (Doctrow et al., unpublished data), in a
model in which catalase activity of a compound is related to its
cytoprotective activity [5]. Attempts to increase the lipophilicity of
cyclized salen manganese complexes have included EUK-207 analogs
with aromatic bridge structures [20] or 5,5′-alkoxy substituents
(Doctrow et al., unpublished). Such compounds were not appreciably
more effective than EUK-207 in cellular models and, in some cases,
were more toxic. The orally available “EUK-400 series” compounds
were, for the most part, substantially more lipophilic than the salen Mn
complexes to which they were compared. However, the most
cytoprotective, least toxic Mn porphyrin, EUK-451, was the least
lipophilic, with a negative logP value (Table 1), more similar to those
of the salen Mn complexes than to the other “EUK-400 series”
compounds [70]. While not conclusive, such observations do suggest
that too much lipophilicity, besides making an agent difficult to
formulate, could have toxicology implications. Overall, several factors
such as lipophilicity, inherent stability, potential toxicity and, of course,
in vivo efficacy must be weighed against one another in selecting a
lead compound. The preponderance of data, in vitro as well as in vivo,
indicates that EUK-207 exhibits a number of properties that justify its
selection as a lead salen Mn complex.

Safety and tolerability
As with any class of therapeutic agent, the safety and
tolerability of salen Mn complexes must be determined in the course of
a normal drug development program. To date, salen Mn complexes
have not undergone formal clinical testing. Salen Mn complexes, as
noted above, are substantially less cytotoxic than Mn porphyrins such
as the “EUK-400 series” compounds [70]. They are also well tolerated
in chronic administration, for example, EUK-189 and EUK-207 were
given to aged mice by continuous infusion for up to 6 months with no
adverse effects noted [21]. The original prototype EUK-8 was given to
mice by repeated injections (30 mg/kg ip, 3 times per wk) for 24 wks
with no discernable impact on mortality, body weight or gross
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pathology assessment [16]. As discussed above [42, 70], EUK-189
and EUK-207 displayed no cytotoxicity under conditions where the
“EUK-400 series” of Mn porphyrins did. Among a series of salen Mn
complexes, those analogs that did exhibit toxicity in cell culture and in
vivo included those that were less stable, apparently releasing toxic
metabolites [5]. The renal injury model studies, however, do indicate
that EUK-207 can cause localized reactions at high doses in irradiated
skin, though this might not occur in other strains or species and other
methods of delivery, even other formulations, might overcome this
issue.

The role of the metal in a metal-ligand complex
The presence of a metal, even one such as Mn that is normally
present in vivo, would be a potential toxicity concern for any agent,
and would need to be addressed. Indeed, toxicity issues aside, the role
of free metal, either as a contaminant [95], transferred by a metalmetal exchange or released via metabolism of the complexes, in the
biological effects of any synthetic metal ligand complex is also an issue
relevant to its mechanism(s) of action. In the case of salen Mn
complexes, structure-activity relationship studies showed that Mn
acetate salts had no catalase activity or cytoprotective properties,
though they show SOD activity [5]. It is also of note that, among salen
Mn complexes, more stable metal-ligand complexes show greater
potency in cytoprotective assays, for example, EUK-207 is effective at
lower doses than EUK-189 at preventing apoptosis, while the two
compounds have similar catalytic properties [70] and essentially
equivalent potency at protecting cells against extracellular hydrogen
peroxide, where, unlike the apoptosis assay, intracellular stability of
the salen Mn complex is not a factor (Doctrow et al., unpublished
data). Other analytical controls, such as ESI-MS, chelator incubation
studies [70, 95] and catalytic activity analysis of HPLC peaks
corresponding to the intact metal-ligand complex can provide evidence
that free metal contaminants are either not detectable, or are not
responsible for biological properties of interest in vitro [70]. However,
such control experiments cannot rule out the possibility, which exists
for any therapeutically investigated metal-ligand complex, that the
drug functions in part by delivering active metal to some site of action.
Indeed, effective delivery of Mn could very well be a component of the
in vivo mechanism of action of salen Mn complexes, Mn porphryins,
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and other biologically active metal ligand complexes. Though such
complex mechanistic questions are difficult to address, future research
in the field might help to illuminate them. More broadly, because of
the interesting, potentially promising biological activities of metals as
components of inorganic complexes, the field of “Metals in Medicine”,
or medicinal inorganic chemistry, is of growing importance [96, 97]. At
least three other classes of Mn-containing compounds have undergone
clinical testing, either as diagnostic imaging agents [98] or
experimental therapeutics [99, 100]. This should help to pave the way
for developing new classes of Mn-based therapeutic agents such as
salen Mn complexes.

V. Conclusion
Synthetic SOD/catalase mimetics, particularly the salen Mn
complexes exemplified by EUK-189 and EUK-207, mitigate radiation
injury to normal tissues, including lung, kidney, skin and oral mucosa.
These findings indicate that these agents could have potential value as
adjunct therapies following radiation therapy. Future development of
salen Mn complexes should focus on optimizing their methods of
delivery and increasing an understanding of their mechanisms of
action and potential side effects.
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Fig 1.

Structures of salen Mn complexes: EUK-8, EUK-134, EUK-189 and

EUK-207
SOD and catalase activities, cytoprotective, and other properties of EUK-207 [17, 20]
and the non-cyclized salen Mn complexes [5] have been described. The structures of
the non- cyclized salen Mn complexes are: EUK-8, R=H, X=Cl; EUK-134, R =
methoxy, X = acetoxy; EUK-189, R = ethoxy; X = acetoxy; EUK-207: OAc = acetoxy
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Fig 2.

Plasma levels of EUK-207 and EUK-189 following sc injection in rats

Compounds (50 mg/kg and 62.5 mg/kg, respectively) were given as a single sc
injection to WAG/RijCmcr rats and blood samples collected by orbital bleeding,
collected into heparinized tubes. Plasma was extracted and quantitated for salen Mn
complexes using LC- MS/MS as described previously [70]. Mean ± SD of n = 4 and 5,
respectively. EUK-189 was undetectable at the last time point.
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Fig 3.

Radiation-induced mitochondrial abnormalities in rat astrocytes

Rat astrocytes were cultured and exposed to ionizing radiation as described previously
[101] A. ATP levels, assayed 4 days after irradiation using the luciferin/luciferase
assay [102]. B. Mitochondrial mass, assayed 4 days after irradiation, using
MitoTracker Green fluorescence measured with flow cytometry, as described [103].
Data are means ± SEM for n = 3; * indicates significantly different from unirradiated
group (p<0.05).
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Fig 4.

Dose-dependent mitigation of respiratory chain effects in irradiated

astrocytes by EUK-134
Rat astrocytes were cultured and exposed to ionizing radiation as described for Fig. 3.
EUK-134 was added immediately after irradiation, where indicated. On day 4 after
irradiation, cells were harvested and respiratory chain complex activities measured as
previously described for Complex I [104], Complex II [105], and Complex III [106]. Y
axis indicates percent of the activity of the unirradiated control cells. Data are means
± SEM for n=3. ** indicates significantly different from unirradiated (no EUK-134); *
indicates significantly different from 30 Gy (no EUK-134) (p<0.05).
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Fig 5.

Time course of EUK-134 mitigation of mitochondrial effects in

irradiated astrocytes
Experiment was conducted as described for Fig 4, except that EUK-134 (50 uM) was
added at the indicated time, in hours, after irradiation. * indicates significantly
different from 30 Gy (no EUK-134).
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Fig. 6.

Breathing rates in rat lung injury model

Breathing rate (mean breaths per minute) is given as a function of time after
irradiation (10 Gy) for rats receiving no radiation (Control), radiation only (IRR) or
radiation plus EUK-207 (IRR + EUK). Additional experimental details are described in
the text and in the original study [52]. Drug treatments started immediately after
irradiation and finished at 14 weeks. Each point represents the mean (±SEM) for all
rats available for analysis at the different times. Statistical analysis (Tukey’s method,
p<0.05) showed that the breathing rate in IRR + EUK rats did not differ from that of
controls and that both differed from IRR.
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Fig 7.

Nucleic acid oxidation (8OHdG levels) in rat lung injury model

Experimental details of the lung injury model, drug treatment, and statistical analysis
are as described for Fig 6. Lung tissue was extracted and analyzed by
immunohistochemistry for 8- OHdG as described [52]. The assays were performed at
0, 4, 8, 14 and 28 weeks following irradiation. Percent positivity is the ratio of positive
pixels/total number of positive and negative pixels in the tissue section (air spaces
excluded). Each bar (A) or each point (B) represents the mean (±SEM). The 8OHdG
levels in the EUK+IRR treated group was significantly lower than in IRR, and did not
differ from that of the Control group, at all time points following irradiation (4 - 28
wks).
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Fig 8.

Collagen synthesis (hydroxyproline content) in rat lung injury model

Experimental details of the lung injury model and drug treatment are as described for
Fig 6. Hydroxyproline content (μg of hydroxyproline/100 mg of wet lung tissue) was
determined as described [52] in lung tissue collected at 28 weeks following irradiation.
Each bar represents the mean (±SEM). Data from unirradiated controls were obtained
from lungs from rats with ages corresponding to the time of radiation (age 7–8 wks),
“young” and 28 wks later, “old”. The hydroxyproline content of the “Radiation only”
group was significantly higher than that of the other groups, which did not differ from
one another.
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Fig 9. EUK-207 mitigates radiation induced loss of angiotensin converting
enzyme (ACE) activity in the rat lung
Experiment in WAGRijCmcr rats subjected to TBI (11 Gy) followed by BMT was
conducted as described in the text and ACE activity was measured in isolated perfused
lungs 6 wks after irradiation as described. Total lung ACE activity is represented as the
mean surface area product [ml/min] based on a spectrophotometrically monitored
substrate cleavage [53]. The data are means ± SEM, for n= 9 (No radiation), 7 (11
Gy), and 8 (11 Gy+EUK-207). * indicates significant difference from the 11 Gy group
(one way ANOVA followed by Bonferroni’s t test).
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Fig 10.

Mitigation of radiation renal injury by EUK-207 but not EUK-189

WAG/RijCmcr rats were subjected to TBI (9 Gy) followed by BMT and renal injury
monitored as described in the text. Salen Mn complexes were administered by
continuous sc infusion for 12 wks, beginning 3 wk after irradiation, as described in the
text. The infusion was based on constant volume delivery, resulting in a dose of 8 to
10 mg/kg-day. The data are mean BUN for n=6 and error bars indicate 95%
confidence intervals. * is significantly different from TBI only (p<0.01, Mann-Whitney).
Normal range of BUN in these rats is 18 to 22 mg/dL.
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Fig 11.

Mitigation of radiation renal injury by EUK-207 and captopril

Experiment was conducted as described for Fig 10, except that the TBI dose was 10
Gy. EUK-207 was given as described for Fig 10. Captopril (12 - 15 mg/kg-day) was
administered in the drinking water over the same treatment period. The data are
mean BUN for n=6 to 7 and error bars indicate 95% confidence intervals. *, # denotes
difference from TBI only (p<0.01, #p<=.07, Mann-Whitney). Normal range of BUN in
these rats is 18 to 22 mg/dL.
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Fig 12.

Improvement of radiation-induced ulcerative mucositis in the

hamster by EUK-189
The hamster mucositis model and scoring system are described in the text and in a
previous study [69]. EUK-189 dosing was topical (T) or subcutaneous (SC), using
protocols described in the text. The figure shows the percent animal days with a
mucositis score ≥ 3. Group sizes were n = 8. * indicates statistically different from
corresponding vehicle control group (chi square). The T and SC control groups were
not significantly different from one another.
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Table 1.

Summary of properties of selected synthetic SOD/catalase

mimetics
Relevant properties, discussed further at various places in the text, are
summarized here. EUK-207 and EUK-189 are salen Mn complexes (Fig 1) and EUK423, EUK-418, and EUK-451 are orally available Mn porphyrin complexes, with
structures as reported by Rosenthal et al. [70]. Superoxide dismutase (SOD), catalase
(CAT) and peroxidase (PX) activities were assayed as described [70]. SOD activity is
represented as an IC50 (μM), so lower values represent higher SOD activity. CAT and
PX are expressed as reaction rates (μM/minute). LogP values were determined by
octanol-water partitioning, as described [70]. Stability to synthetic gastric solution
(SGF), determined as described [70], shows the percent of compound remaining after
90 min at 37°C. Stability to EDTA, determined as described [17], shows the percent of
compound remaining after incubation at ambient temperature in a 114-fold molar
excess of EDTA for 3.2 or 70 hr, as indicated. All data are reprinted from the cited
articles. Error bars represent SD for triplicate determinations. nd indicates not done
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Table 2.

Mitigation of radiation renal injury with EUK-207 (sc daily)

Renal injury was induced in WAG/Rij rats using TBI/BMT as described in the text. The
radiation dose was 10 Gy. Rats treated with EUK-207, at the indicated daily doses,
received sc injections beginning 48 hr after irradiation and continuing for 10 wks.
Proteinurea (UP/UC) was measured at 9 and 17 weeks. BUN was measured at 9, 17,
21 weeks and at sacrifice. Blood pressure (BP) was measured at 17 weeks. The
median survival and range are shown in the first data column. The data for other
parameters are means (with 95% confidence levels); n = 9–10. Results of statistical
testing (Mann-Whitney, corrected for multiple comparisions):

a

p<0.05 vs age-matched normal;

b

p<0.05 vs TBI alone; all other comparisons p>0.10

*

time to BUN=120 (with range)
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